Quantitative Xylazine Measurement in ED
- Conditions
- Opioid OverdoseSubstance Use Disorders
- Registration Number
- NCT06949605
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Brief Summary
Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)
- Detailed Description
Xylazine, a veterinary medication and alpha-2 agonist drug with clinical effects including prolonged sedation and skin/soft tissue wounds, has been increasingly detected with fentanyl in the illicit opioid supply. Due to its rapid emergence, limited knowledge exists regarding xylazine's health effects. In this proposed research, Dr. Love will measure xylazine and its metabolites in blood and urine samples using laboratory and point-of-care assays. Working at two New York City emergency departments, Dr. Love will collect waste serum and urine from opioid overdose patients to measure xylazine and its metabolite concentrations. The researcher will also perform qualitative assessment of urine samples with xylazine test strips to characterize urine xylazine detection using a harm reduction tool.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 15
- ED patient
- Opioid OD (both NPS and non-NPS)
- Availability of waste blood specimens for analysis
- Availability of waste urine specimens for analysis
- Children under 18
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Xylazine Concentration in Blood 6 months Concentration of Xylazine in blood as determined by lab.
- Secondary Outcome Measures
Name Time Method Xylazine Strip Specificity and Sensitivity 6 months Measuring Xylazine test strip specificity and sensitivity using excess urine samples.
Trial Locations
- Locations (2)
NYC Health + Hospitals/Elmhurst
🇺🇸Elmhurst, New York, United States
Icahn School of Medicine
🇺🇸New York, New York, United States